259 related articles for article (PubMed ID: 3120317)
1. The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
Levin L; Hryniuk W
Semin Oncol; 1987 Dec; 14(4 Suppl 4):12-9. PubMed ID: 3120317
[TBL] [Abstract][Full Text] [Related]
2. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
[No Abstract] [Full Text] [Related]
3. [Palliative chemotherapy of endometrial cancer. Value of combinations with doxorubicin and cisplatin].
Chauvergne J; Granger C; Mage P; Pigneux J; David M
Rev Fr Gynecol Obstet; 1986 Oct; 81(10):547-51. PubMed ID: 2431448
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
5. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy in advanced forms of carcinoma of the ovary].
Calciati A; Clerico M; Donadio M; Giaccone G
Minerva Ginecol; 1984 Apr; 36(4):195-8. PubMed ID: 6431334
[No Abstract] [Full Text] [Related]
8. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
9. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
Levin L; Simon R; Hryniuk W
J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival of patients with advanced ovarian carcinoma treated with cisplatin-based chemotherapy regimens.
De Pree N; Wils J
Anticancer Res; 1989; 9(6):1869-71. PubMed ID: 2697190
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of advanced ovarian cancer].
de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy of epithelial ovarian carcinoma].
Bruntsch U; Gallmeier WM
MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
[No Abstract] [Full Text] [Related]
13. [High-dose chemotherapy in ovarian adenocarcinoma].
Lotz JP; Lhommé C; Pautier P; Couteau C; Gligorov J; Alexandre J; Selle F; Izrael V; Maraninchi D; Viens P
Bull Cancer; 2000 Jan; 87(1):63-9. PubMed ID: 10673633
[No Abstract] [Full Text] [Related]
14. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
Schwartz PE; Lawrence R; Katz M
Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
Piver MS; Lele S; Barlow JJ
Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
[TBL] [Abstract][Full Text] [Related]
16. Options for primary chemotherapy in advanced ovarian cancer: the European perspective.
Colombo N; Maggioni A; Vignali M; Parma G; Mangioni C
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S108-13. PubMed ID: 7835793
[TBL] [Abstract][Full Text] [Related]
17. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
[No Abstract] [Full Text] [Related]
18. Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy.
Sessa C; Bolis G; Valente I; Mangioni C; D'Incalci M
Cancer Treat Rep; 1981; 65(1-2):172-3. PubMed ID: 6784922
[No Abstract] [Full Text] [Related]
19. [Current role of chemotherapy in the treatment of adenocarcinomas of the endometrium].
Chauvergne J; Avril A; Pigneux J; Mage P; Granger C
Bull Cancer; 1986; 73(6):675-9. PubMed ID: 3105628
[No Abstract] [Full Text] [Related]
20. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Mäenpää J; Kangas L; Grönroos M
Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
